Alpha Paradigm Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Alpha Paradigm Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-17,850	Closed	-$1.51M	–	486
2022 Q3	$1.51M	Buy	+17,850	New	+$1.59M	0.66%	27
2022 Q2	–	Sell	-8,855	Closed	-$683K	–	508
2022 Q1	$683K	Sell	8,855 -2,358	-21%	-$197K	0.27%	112
2021 Q4	$991K	Sell	11,213 -8,013	-42%	-$661K	0.4%	59
2021 Q3	$1.49M	Buy	+19,226	New	+$1.52M	0.6%	31

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Alpha Paradigm Partners's BMRN Position: Q4 2022 in Review

Alpha Paradigm Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2022, closing a stake of 17,850 shares — an estimated $1.51M sold.

Alpha Paradigm Partners first reported a position in BMRN in Q3 2021 and held it in 4 quarters. The position peaked at $1.51M in Q3 2022. 580 funds tracked by Wall St. Rank hold BMRN as of Q4 2022.

Alpha Paradigm Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Alpha Paradigm Partners sold 17,850 BioMarin Pharmaceuticals shares in Q4 2022, an estimated $1.51M.
Alpha Paradigm Partners first reported a position in BioMarin Pharmaceuticals in Q3 2021 and held it in 4 quarters.
Alpha Paradigm Partners's BioMarin Pharmaceuticals position peaked at $1.51M in Q3 2022.
580 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.